Source: https://www.google.be/patents/US8846115
Timestamp: 2017-11-21 13:53:33
Document Index: 77704263

Matched Legal Cases: ['art 1995', 'art 1999', 'art 2004', 'art 2003', 'Application No. 02737562', 'Application No. 02784313', 'Application No. 05851567', 'Application No. 05723895']

Patent US8846115 - Anti-inflammatory cyclooxygenase inhibitors - Google Patenten
Disclosed is a pharmaceutical composition including a therapeutic quantity of a COX-2 inhibitor having an IC50-WHMA COX-2/COX-1 ratio ranging from about 0.23 to about 3.33 with reduced gastrointestinal and cardiovascular toxicity. Also disclosed are methods for treating osteoarthritis, rheumatoid arthritis...https://www.google.be/patents/US8846115?utm_source=gb-gplus-sharePatent US8846115 - Anti-inflammatory cyclooxygenase inhibitors
Publicatienummer US8846115 B2
Aanvraagnummer US 14/072,748
Publicatiedatum 30 sept 2014
Aanvraagdatum 5 nov 2013
Prioriteitsdatum 13 nov 2001
Ook gepubliceerd als US8158160, US8609154, US20030091656, US20120270951, US20140066520
Publicatienummer 072748, 14072748, US 8846115 B2, US 8846115B2, US-B2-8846115, US8846115 B2, US8846115B2
Uitvinders Eric Hauser Kuhrts
Oorspronkelijke patenteigenaar Metaproteomics, Inc.
Patentcitaties (167), Niet-patentcitaties (188), Classificaties (6), Juridische gebeurtenissen (1)
US 8846115 B2
EP1938828A1 18 dec 2007 2 juli 2008 Brasseries Kronenbourg Use of lupulones for the prevention and treatment of colorectal cancer
JP2002012550A Titel niet beschikbaar
JP2002505296A Titel niet beschikbaar
JPH04202138A Titel niet beschikbaar
JPH07165583A Titel niet beschikbaar
JPH07194351A Titel niet beschikbaar
JPH09502202A Titel niet beschikbaar
JPH10179129A Titel niet beschikbaar
JPH11246399A Titel niet beschikbaar
JPH11335231A Titel niet beschikbaar
JPH11513037A Titel niet beschikbaar
JPS589084B2 Titel niet beschikbaar
JPS5959623U Titel niet beschikbaar
JPS52145509U Titel niet beschikbaar
WO1995007079A1 24 aug 1994 16 maart 1995 The Procter & Gamble Company Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agents and caffeine
WO1997031630A1 27 feb 1997 4 sept 1997 Regents Of The University Of Minnesota Use of hexahydrolupulones as antibacterial and anticancer agents
WO1997049405A1 24 juni 1997 31 dec 1997 The Procter & Gamble Company Topical gel composition containing a combination of a nsaid and a xanthine derivative
WO1999044623A8 4 maart 1999 14 okt 1999 Linda D Artman Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a nsaid
WO1999061038A1 28 mei 1999 2 dec 1999 Adams Food Ltd. Composition having therapeutic and/or nutritionally active substituent
WO2000068356A3 4 april 2000 15 feb 2001 Yakima Chief Inc Hop extract product of defined composition
WO2002032234A1 17 okt 2001 25 april 2002 Laboratoires Robert Schwartz Anti-stress composition designed to be mainly incorporated in nutritional carriers
WO2003000185A3 20 juni 2002 11 maart 2004 John G Babish Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
WO2003035007A3 25 okt 2002 18 sept 2003 Metaproteomics Llc Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
WO2003068205A1 14 feb 2003 21 aug 2003 Kirin Beer Kabushiki Kaisha Compositions and foods for improving lipid metabolism
WO2003075943A3 6 maart 2003 22 april 2004 Sophie Chen Ph D Botanical extract compositions with anti-cancer or phytoestrogenic activity comprising wogonin, isoliquiritigenin and/or coumestrol
WO2004037180A3 20 okt 2003 30 sept 2004 John G Babish Compositions that treat or inhibit pathological conditions associated with inflammatory response
WO2004062611A3 9 jan 2004 7 april 2005 Eric Kuhrts Anti-inflammatory cyclooxygenase-2 selective inhibitors
WO2005039483A3 21 mei 2004 29 sept 2005 John G Babush Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
WO2005084230A3 26 feb 2005 15 dec 2005 John G Babish Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
WO2006053249A2 14 nov 2005 18 mei 2006 Metaproteomics, Llc Compositions exhibiting inhibition of cyclooxygenase-2
WO2006062681A9 14 nov 2005 3 aug 2006 Metaproteomics Llc Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
WO2007021694A3 9 aug 2006 18 okt 2007 John G Babish Protein kinase modulation by hops and acacia products
WO2007067812A3 11 dec 2006 28 feb 2008 Metaproteomics Llc Protein kinase modulation by hops and acacia products
WO2009124176A1 2 april 2009 8 okt 2009 Metaprotemics, Llc Substituted 1,3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions
2 Albal, MV., et al., "Clinical evaluation of berberine in mycotic infections," Indian J. Ophthalmol 34:91-2 (1986).
3 Anio, et al., "Anti-inflammatory Activity of Natural and Synthetic Curcuminoids", Pharmacy and Pharmacology Communications, 4(2), pp. 103-106 (1998).
5 Bermejo, et al. Rev. Esp. Enferm. Dig. 95(9): 621-624 and 625-628 (2003)
13 Charlier, et al. Eur. J. Med. Chem. 38-645-659 (2003).
14 Chattopadhyay et al., Current Science, 87(1) (Jul. 10, 2004).
18 Chou, et al. Eur. J. Biochem, 115:207-216 (1981).
25 Communication re EP 098253263 (Jan. 24, 2012).
26 Costa, et al. Digest: Liver Dis. 35:642-647 (2003).
30 Ding, et al. Biochem. Biophy, Res. Comm. 261:218-223 (1999).
31 European Examination Report for EP App. No. 02748188.6-1216 (Apr. 28, 2011).
32 European Search Report EP 05 723 839.6 (Jan. 22, 2010).
33 European Search Report EP 10006768 (Oct. 28, 2010).
34 European Search Report EP 10011254 (Jan. 31, 2011).
35 European Search Report EP 10013109 (Dec. 14, 2010).
36 European Search Report EP 10162893 (Sep. 14, 2010).
37 European Search Report for corresponding EP Application No. 02737562.5 (4 pages) (Dec. 14, 2004).
38 European Search Report for EP App. No. 07809709.4 (Jan. 4, 2010).
39 European Search Report for related European Application No. 02784313.5 (Nov. 27, 2006).
40 Examination Report re: Australian App. No. 2006321727 corresponding to PCT/US06/047196 (May 5, 2011).
41 Examination Report re: New Zealand App. No. 581064 corresponding to PCT/US08/053803 (May 9, 2012).
42 Exercise as Treatment for Arthritis, Rheumatic and Immunologic Diseases, Cleveland Clinic, www.clevelandclinic.org, Mar. 14, 2000.
43 Exmination Report re: Australian App. No. 2009231723 corresponding to PCT/US09/39272 (Jun. 26, 2012).
44 Extended European Search Report EP 07717798.8 (Jun. 29, 2010).
45 Extended European Search Report EP 07809708.6 (Jan. 5, 2010).
46 Extended European Search Report EP 10162893.1 (Oct. 12, 2010).
47 Extended European Search Report EP06728126.5 (Feb. 16, 2012).
48 Extended European Search Report EP08732208.7 (May 24, 2012).
49 Fiebich et al., Effects to caffeine and paracetamol alone or in combination with acetylsalicytic acid on prostaglandin E2 synthesis in rat microglial cells; Neuropharmacology 39:2205-2213 (2000).
50 Foucault et al., J. Chromatography A 808(1-2):3-22 (May 29, 1998); abstract only (3 pages).
51 Friedman, et al. J Cutan Med. Surg. 6(5):449-459 (2002).
52 Gao et al., J. Food Sci. Nutr. vol. 9, pp. 240-244 (2004).
53 Gerhauser et al., Molecular Cancer Therapeutics vol. 1, No. 11, pp. 959-969 (2002).
54 Gerhauser, Beer Constituents as Potential Cancer Chemopreventive Agents, EP Journal of Cancer 41: 1941-1954: (2005).
55 Germany, "The Absolutely German Drink." contents of beer, 2004, 5 pages.
56 Gilani, "Studies on Antihypertensive and Antispasmodic Activities of Methanol Extract of Acacia nilotica Pods", Phytotherapy Research 13: 665-669 (1999).
57 Goldstein, et al. Am. J. Gastroenterol, 96(4): 1019-1027 (2001).
58 Haiter, et al. Gut 49:443-453 (2001).
59 Hamberg, et al. J. Bio. Chem. 246(22);6713-6721 (1971).
60 Hariddradilepah 01, TKDL, Aug. 1, 1999, XP003024376, (3 pages).
61 Huarig, et al. Cancer Res. 51:813-819 (1991).
62 Information on "ArthroTrimTM product", downloaded from Internet Aug. 30, 2002.
63 Information on "Hops and Beer Flavours", IOB Technical Symposium, Apr. 2001, pp. 1-9.
64 Information on "Zyflamend and Zyflamend PM", downloaded from Internet Aug. 30, 2002.
65 International Search Report for Corresponding PCT Application No. PCT/US05/41018; 2pp (May 30, 2008).
66 International Search Report for PCT /US06/30920, Aug. 3, 2007, 3 pages (Aug. 30, 2007).
67 International Search Report for PCT/US02/19617 (Jun. 17, 2003).
68 International Search Report for PCT/US04/16043 (Jul. 27, 2005).
69 International Search Report for PCT/US06/47196 (Dec. 20, 2007).
70 Ivanovska et al., Study on the anti-inflammatory action of berberis vulgaris root extract, alkaloid fraction and pure alkaloids; Int. J. Immunopharmac., 18(10):553-561 (1996).
71 Jach, Przegl Dermatol, 65(4):379-381 (1978).
72 Jafri et al., Pakistan Journal of Science, vol. 61, No. 4, pp. 220-222 (Dec. 2009).
73 Kaltner, Investigation of formation of Hops Aroma and technological Measures for Products of Hops-Aromatic Beers. Technical Univeristy of Munich, 7 pp. corresponding to Kaltner, D., Technische Universitat Munchen; (Nov. 30, 2000), pp. 1-193, plus Tabs. AH1-AH31.
74 Kanematsu, et al. J Bone Miner Res 12(11):1789-1796 (1997).
76 Kuo et al., Cancer Letter, 203:127-137 (2004).
77 Lamy Virginie et al., Apoptosis, an Int'l Journal on Programmed Cell Death. 13(10), pp. 1232-1242 (Aug. 25, 2006).
78 Lamy Virginie et al., Carcinogenesis, 28(7), pp. 1575-1581 (Jul. 2007).
79 Lerman et al, FASEB Journal, Fed. of American Soc. for Experimental Biol. vol. 18, No. 4-5 (Jan. 1, 2004)
80 Lopes, Curr. Med Res Opin. 8(3):145-149 (1982).
81 Lukaczer et al., Phytotherapy Research, vol. 19, No. 10, pp. 864-869 (2005).
82 Mannering et al., Food, Nutrition and Chemical Toxicity X(X), pp. 311-323 (Jan. 1, 1993).
83 Meling, et al, Scand. J. Gastroenterol. 31:339-344 (1996)
84 Minich et al., Journal of nutrition and Metabolism, vol. 2010, article ID 467316, pp. 1-11, (2010).
85 Murvadyaghrtarn, TKDL , Jan. 1, 1990, XP003024379 (4 pages).
86 Murvadyaghrtarn, TKDL, Jan. 1, 2001, XP003024377 (4 pages).
87 Newark, et al., "Beyond Aspirin", pp. 147-151, Hohm Press (2000).
88 Noreen, et al. J. Nat. Prod 61:2-7 (1998).
89 Notice of Allowance issued in U.S. Appl. No. 13/448,623 with date of mailing Aug. 21, 2013.
90 Office Action issued for U.S. Appl. No. 11/667,614 mailed Apr. 16, 2010.
91 Office Action issued for U.S. Appl. No. 11/667,615 mailed Mar. 16, 2010.
92 Office Action issued for U.S. Appl. No. 11/701,583 mailed Feb. 8, 2008.
93 Office Action issued for U.S. Appl. No. 11/701,583 mailed Jul. 6, 2009.
94 Office Action issued for U.S. Appl. No. 11/701,583 mailed Nov. 26, 2008.
95 Office Action issued in U.S. Appl. No. 10/464,410 on May 23, 2011.
96 Office Action issued in U.S. Appl. No. 10/464,834 on Aug. 3, 2010.
97 Office Action issued in U.S. Appl. No. 10/532,388 on Jun. 28, 2011.
98 Office Action issued in U.S. Appl. No. 10/532,388 on Mar. 26, 2010.
99 Office Action issued in U.S. Appl. No. 10/532,388 on Oct. 1, 2010.
100 Office Action issued in U.S. Appl. No. 10/590,301 on Aug. 19, 2010.
101 Office Action issued in U.S. Appl. No. 10/590,424 on Jun. 29, 2010.
102 Office Action issued in U.S. Appl. No. 10/789,814 on Jun. 11, 2010.
103 Office Action issued in U.S. Appl. No. 10/789,814 on Mar. 18, 2011.
104 Office Action issued in U.S. Appl. No. 11/344,552 on Sep. 8, 2010.
105 Office Action issued in U.S. Appl. No. 11/344,555 on Jan. 19, 2011.
106 Office Action issued in U.S. Appl. No. 11/344,556 on Dec. 16, 2009.
107 Office Action issued in U.S. Appl. No. 11/344,556 on Mar. 27, 2009.
108 Office Action issued in U.S. Appl. No. 11/344,556 on Sep. 3, 2010.
109 Office Action issued in U.S. Appl. No. 11/344,557 on Apr. 21, 2008.
110 Office Action issued in U.S. Appl. No. 11/344,557 on Aug. 28, 2009.
111 Office Action issued in U.S. Appl. No. 11/344,557 on Jan. 10, 2007.
112 Office Action issued in U.S. Appl. No. 11/344,557 on Mar. 25, 2010.
113 Office Action issued in U.S. Appl. No. 11/344,557 on Sep. 26, 2007.
114 Office Action issued in U.S. Appl. No. 11/501,393 on Aug. 25, 2010.
115 Office Action issued in U.S. Appl. No. 11/501,393 on Nov. 9, 2011.
116 Office Action issued in U.S. Appl. No. 11/636,867 on Aug. 30, 2010.
117 Office Action issued in U.S. Appl. No. 11/636,867 on Mar. 8, 2011.
118 Office Action issued in U.S. Appl. No. 11/636,867 on Oct. 28, 2011.
119 Office Action issued in U.S. Appl. No. 11/649,584 on Mar. 3, 2010.
120 Office Action issued in U.S. Appl. No. 11/729,696 on Jul. 14, 2011.
121 Office Action issued in U.S. Appl. No. 11/729,696 on Mar. 25, 2010.
122 Office Action issued in U.S. Appl. No. 11/729,696 on Nov. 1, 2010.
123 Office Action issued in U.S. Appl. No. 11/820,600 on May 26, 2011.
124 Office Action issued in U.S. Appl. No. 11/820,600 on Sep. 30, 2010.
125 Office Action issued in U.S. Appl. No. 11/820,607 on May 23, 2011.
126 Office Action issued in U.S. Appl. No. 11/820,607 on Oct. 12, 2010.
127 Office Action issued in U.S. Appl. No. 11/820,653 on Aug. 8, 2011.
128 Office Action issued in U.S. Appl. No. 11/820,755 on Jun. 1, 2011.
129 Office Action issued in U.S. Appl. No. 11/820,755 on Oct. 18, 2010.
130 Office Action issued in U.S. Appl. No. 12/030,335 on Oct. 21, 2010.
131 Office Action issued in U.S. Appl. No. 12/048,613 on Dec. 8, 2010.
132 Office Action issued in U.S. Appl. No. 12/331,887 on Jul. 5, 2012.
133 Office Action issued in U.S. Appl. No. 12/331,887 on Oct. 12, 2011.
134 Office Action issued in U.S. Appl. No. 12/626,392 on Jul. 8, 2011.
135 Office Action issued in U.S. Appl. No. 12/626,392 on Oct. 27, 2010.
136 Office Action issued in U.S. Appl. No. 12/634,877 on May 9, 2012.
137 Office Action issued in U.S. Appl. No. 12/754,820 on Mar. 15, 2011.
138 Office Action issued in U.S. Appl. No. 12/754,820 on Nov. 30, 2011.
139 Ohkura et al., Japanese Joural of Pharmacognosy, 44(3):171-175, (1990).
140 Panglisch, Monafsschrift fuer Brauwissen Schaft, 43(1), 4-16 (1990).
141 Pariel, et al. Inflamm. Res 47, Supplement 2S93-S101 (1998).
142 Parmar et al., Phytochemistry, vol. 28(2):591-593 (1989).
143 Parts per Milliion, 1 page, 2004.
144 Pippa, et al. Scand. J. Gastroenterol. Suppl. 167:32-35 (1989).
145 Plewig, et al. J Invest. Dermatol. 65(6):532-536 (1975).
146 Poullis, et al. J. Gastroenterol. Hepatol. 18:756-762 (2003).
147 Provital Group, Rosemary-eco Botany, 2007, 9 pages.
148 Q & A, (what does ppm or ppb mean?) 3 pages, 2004.
149 Rahman, M.M., et al., "Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling" J. Lipid Res., 47(8): 1739-1748, (2006).
150 Ringbom, et al. J. Nat Prod 61:1212-1215 (1998).
151 Røseth, Digest. Liver Ris. 35:607-609 (2003).
152 Schjerven, et al. Br. J. Dermatol. 149:484-491 (2003).
153 Schmalreck et al, Canadian Journal of Microbiology, vol. 21:205-212 (1975).
154 Shah, et al. Gut 48:339-346 (2001).
155 Shimamura, et al. Biochem. Biophys. Res. Comm. 289:220-224 (2001).
156 Shureiqi, et al. Cancer Res. 61:6307-6312 (2001).
157 Sivri, Fundam. Clinic. Pharmacol. 18:23-31 (2004).
158 Smith, et al., Natural Foam Stabilizing and Bittering Compounds Derived From Hops, Journal of the American Society of Brewing Chemists, vol. 56, No. 2, 1998, pp. 52-57.
159 Stephan T E et al., Biochemical Pharmacology, 55(4), pp. 505-514, (Feb. 15, 1998).
160 Stevens, Xanthohumol and related Prenylflavonoids from Hops and Beer: To Your Good Health, Science Direct, 2pp (2004).
161 Subbaramaiah, et al. Cancer Res. 60:2399-2404 (2000).
162 Suh. et al. Cancer Res 58:717-723 (1988).
163 Supplementary European Search Report for EP Application No. EP 08859091, 5PP.
164 Supplementary European Search Report from related EP Application No. 05851567, 8PP.
165 Supplementary Partial European Search Report for related European Patent Application No. 05723895 8, 5 pages (2007).
166 The national. 3 pages (1999).
167 Tibble, et al. Drugs Today 37(2):85-96 (2001).
168 Tibble, et al. Gut 45:362-366 (1999).
169 Tiktakaghrtam, TKDL, Jan. 1, 1922, XP003024378 (1922).
170 Tobe, et al. Biosci. Biotech. Biochem 61(1):158-159 (1997).
171 Turmeric: The Ayurvedic Spice of Life, published at www.bioponic.com/pdfs/TurmericAyurveda.pdf (2003).
172 US News and world report re Palliative Care, 10 pages (2008).
173 Van Cleemput, Hop (Humulus lupulus)-derived bitter acids as multipotent bioactive compounds; J. Nat. Prod. 72:1220-1230 (2009).
174 Van Montfrans et al. Inflammatory Signal Transduction in Crohn's Disease and Novel Therapeutic Approaches, Science Direct, Jun. 2, 2002, 20 pages. Biochemical Pharmacology. vol. 64, issues 5-6.
175 Vanhoecke et al., In Vivo, vol. 19, No. 1, pp. 103-107 (2005).
176 Vanhoenacker, et al., Journal of Chromatography, vol. 1035, No. 1, (Apr. 30, 2004) pp. 53-61.
177 Verzele and De Keukeleire (eds.) Chemistry and Analysis of Hop and Beer Bitter Acids; Elsevier, Chapters 5, 20 pages (1991).
178 Verzele and De Keukeleire (eds.) Chemistry and Analysis of Hop and Beer Bitter Acids; Elsevier, Chapters 6, 8 pages (1991).
179 Verzele, et al. Chemistry and analysis of hop and better bitter acids, Developments in food science, 27, pp. 44-51, 88-139 (1991).
180 Wang, et al. Free Radical Biology & Medicine 27:612-616 (1999).
181 Ward, et al., Therapeutic Potential of Phosphoinositide 3-Kinase inhibitors, Chemistry & Biology, vol. 10, 207-210, Mar. 2003.
182 Warner, et al. Proc Natl Acad Sci USA 96:7563-7568 (1999).
183 Wassel et al., Phytochemical examination and biological studies of Acacia . . . , Egyptian Journal of Pharaceutical Sciences, vol. 33 (1-2):pp. 327-340, 1992.
184 Written Opinion for corresponding PCT Application No. PCT/US05/41018; 3 pp (May 30, 2008).
185 Yamamoto, et al. Abstract—Prostaglandins & Other Lipid Mediators 59:1-2325 (1999).
186 Yamamoto, FEBS Letters 465:103-106 (2000).
187 Yui, et al. Biol Pharm. Bull. 26(6):753-760 (2003).
188 Zhao Feng et al., Biological and Pharmaceutical Bulletin, 26(1), pp. 61-65 (Jan. 2003).
Internationale classificatie A61K31/201, A61K31/122, A01N65/00
Coöperatieve classificatie A61K31/122, A61K31/201